Savara (SVRA) Current Deferred Revenue (2018 - 2020)

Savara's (SVRA) quarterly Current Deferred Revenue came in at $243000.0 in Q2 2020, up 2.1% on a QoQ basis from $238000.0 in Q1 2020.

Savara (SVRA) Current Deferred Revenue (2018 - 2020) Analysis & Trends

Savara (SVRA) has 3 years of Current Deferred Revenue data on file, last reported at $243000.0 in Q2 2020.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $243000.0 in Q2 2020; TTM through Jun 2020 was $243000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $250000.0, changed N/A from the prior year.
Current Deferred Revenue for Q2 2020 stood at $243000.0, up from $238000.0 in the prior quarter.
Over the last five years, Current Deferred Revenue for SVRA reached as high as $250000.0 in Q4 2018 and fell as low as $238000.0 in Q1 2020.
Historically, Current Deferred Revenue has averaged $243250.0 across 3 years, with a median of $242500.0 in 2019.
On a YoY basis, Current Deferred Revenue climbed as much as 1.65% in 2020 and fell as far as 1.65% in 2020.
Year by year, Current Deferred Revenue stood at $250000.0 in 2018, then fell by 3.2% to $242000.0 in 2019, then advanced by 0.41% to $243000.0 in 2020.
Per Business Quant data, the three most recent Current Deferred Revenue figures were $243000.0 in Q2 2020, $238000.0 in Q1 2020, and $242000.0 in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Savara	1.24 Bn	1.24 Bn	-

Download Data